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A B S T R A C T
A majority of cancer diagnoses and deaths occur in patients age  65 years. With the aging of the
US population, the number of older adults with cancer will grow. Although the coming wave of
older patients with cancer was anticipated in the early 1980s, when the need for more research
on the cancer-aging interface was recognized, many knowledge gaps remain when it comes to
treating older and/or frailer patients with cancer. Relatively little is known about the best way to
balance the risks and benefits of existing cancer therapies in older patients; however, these
patients continue to be underrepresented in clinical trials. Furthermore, the available clinical trials
often do not include end points pertinent to the older adult population, such as preservation of
function, cognition, and independence. As part of its ongoing effort to advance research in the field
of geriatric oncology, the Cancer and Aging Research Group held a conference in November 2012
in collaboration with the National Cancer Institute, the National Institute on Aging, and the Alliance
for Clinical Trials in Oncology. The goal was to develop recommendations and establish research
guidelines for the design and implementation of therapeutic clinical trials for older and/or frail
adults. The conference sought to identify knowledge gaps in cancer clinical trials for older adults
and propose clinical trial designs to fill these gaps. The ultimate goal of this conference series is
to develop research that will lead to evidence-based care for older and/or frail adults with cancer.
J Clin Oncol 32:2587-2594. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Cancer is a disease of aging, with the majority of
patients age  65 years.1 Cancer incidence is ex-
pected to increase by 67% among individuals age 
65 years from 2010 to 2030.2 Furthermore, because
those diagnosed with cancer are also living longer,
the proportion of cancer survivors age  65 years
will increase by 42% between 2010 and 2020.3 This
demographic wave of older patients with cancer was
anticipated as early as the 1980s, leading to calls for
greater attention to geriatric oncology and for in-
creasing the interface between cancer and aging. B.J.
Kennedy, MD, then president of the American So-
ciety of Clinical Oncology, predicted that cancer and
aging would become a major problem in the United
States.4 Yancik et al5 described the changing age
structure of the nation’s population and the discrep-
ancy between chronologic and physiologic age. They
identified the pressing need for increased research
on cancer and aging.
Although much has been learned about aging
and cancer since then, few clinical trials focus on the
therapeutic decisions most directly facing older
adults. Historically, older adults have been under-
represented in cancer clinical trials, and recent up-
dated data suggest that this remains a significant
concern.6-8 As a result, there is a significant lack of
information on the safety and efficacy of cancer
treatment for the growing numbers of older patients
with cancer. This becomes even more important
because the biology of certain cancers changes with
aging, and therefore, specific studies of the efficacy
of therapeutic approaches are needed across the age
spectrum.9-11 Despite the increased incidence and
prevalence of cancer among older adults, the litera-
ture reports that age-related differences in treatment
patterns persist, with older adults often receiving less
aggressive therapy,12-19 despite the fact that many
older patients with cancer can tolerate and benefit
from cancer-directed therapies. For example, pa-
tients age 70 to 79 years with acute myeloid leuke-
mia fare better with chemotherapy than patients
receiving palliative care.20 Conversely, a subset of
older adults may be at increased vulnerability to
treatment-related toxicities. There is increased un-
derstanding that chronologic age is a weak marker of
physiologic age and that factors captured in a geriat-
ric assessment (GA) can identify older adults at risk
for cancer treatment toxicities.21-26
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Compounding the overall problem is the underrepresentation of
older adults in therapeutic clinical trials6,7,27,28 (Fig 1). Twenty-eight
percent of individuals diagnosed with cancer are age  75 years1;
however,  10% of patients enrolled onto National Cancer Institute
(NCI) Cooperative Group clinical trials are age  75 years.7 Although
the overall number of patients enrolled onto clinical trials has declined
over the past decade, the proportion of older adults in these trials
remains the same. However, the portfolio of studies in the NCI Coop-
erative Group clinical trials was dominated by accrual from breast
cancer trials, which were particularly slanted toward a group of pa-
tients younger than the general population of patients with the disease.
In other disease types, such as prostate cancer, the age distribution of
patients enrolled onto clinical trials was more reflective of the larger
population with the disease.
It is crucial to find ways to improve the accrual of healthy older
adults to existing clinical trials and to develop research studies that
address the knowledge gaps regarding older and/or frail adults who
would not typically be enrolled onto standard trials. Some vital knowl-
edge gaps may not be addressed by the larger phase III cancer trials for
all ages. Those gaps affect the care of patients with physiologic decline
and/or those with comorbid conditions that exclude them from cer-
tain clinical trials, placing them at increased risk for toxicity. Specific
studies targeting those knowledge gaps are needed.
GOALS OF THE CONFERENCE ON OLDER AND/OR FRAIL
PATIENTS IN THERAPEUTIC CLINICAL TRIALS
The Cancer and Aging Research Group (CARG), in collaboration
with the National Institute on Aging (NIA) and the NCI, has been
holding a conference series funded by a U13 grant to examine the level
of evidence and areas of highest research priority in geriatric oncology,
identify strengths in existing research methods, and foster multidisci-
plinary collaboration. The first of these conferences, held in Septem-
ber 2010, found that few therapeutic data exist for patients with cancer
who are age  75 years or who have chronic health conditions.29-31
Conference participants further found that clinical, biologic, and
physiologic markers of age are only rarely or inconsistently incorpo-
rated into clinical trials and that clinical trial infrastructure is often
incompatible with the needs of older patients.
From November 17 to 18, 2012, CARG held the second confer-
ence in collaboration with the NIA, the NCI, and the Alliance of
Clinical Trials in Oncology. The intent of this second conference was
to focus on the design and implementation of therapeutic clinical trials
for older and/or frail adults. The overall goal was to develop clinical
trial designs specifically targeting questions that affect older and/or
frailer adults with cancer, as well as to provide recommendations
and create examples for others interested in geriatric oncology
research. This article summarizes points raised at the conference
and identifies common themes in geriatric oncology clinical trial
design that emerged.
GERIATRICIZING TRIAL DESIGN
Defining the Study Population: Older and/or
Frail Patients
The inclusion of older and/or frail patients in therapeutic clinical
trials is hampered by difficulties in defining and recruiting this popu-
lation. As one aspect of the research design considerations, an effort
was made to define these groups for the purposes of cancer clini-
cal trials.
Defining older. Typically included in cancer clinical trials are the
healthiest and most robust of older patients, with ready access to
specialized cancer centers or clinical oncology programs.32 Those with
second cancers or comorbidities including cognitive or functional
impairments, cardiac disease, or organ dysfunction—all of which are
more likely to occur among older patients—often are either explicitly
excluded from or not actively enrolled onto clinical trials. Conse-
quently, older patients typically seen by oncologists are less likely to
be enrolled onto clinical trials, and those age  75 years are espe-
cially unlikely to be included.6,7,27,28 Considering age alone, those
age  75 years are defined as older for purposes of recruitment and
design efforts.
Defining frail. Recognizing that a consensus has not yet been
reached on a definition of frailty for oncology trials, one goal of this
conference was to clarify the definition for older adults. A geriatric
oncology definition of frailty is suggested: those older individuals who
are at higher risk for cancer treatment toxicity because of age-
associated conditions such as functional losses, cognitive impairment,
or physiologic changes. This is distinct from, although may overlap
with, the geriatrician’s definition of frailty, which is a vulnerable health
condition resulting in a decreased ability to respond to a stressor that is
associated with a higher likelihood of functional decline, disability,
hospitalization, and mortality.33,34 Two well-established ways of mea-
suring frailty have been developed by Fried et al33 and Rockwood and
Mitnitski.35 However, there are limitations in applying these defini-
tions to geriatric oncology, because the definitions were developed for
the general geriatric population and not specifically for older adults
with cancer, whose physiologic stressors may be different. Often the
stressors for a patient with cancer are surgery and/or chemotherapy,
and tools are needed to identify older adults at risk for serious toxicity
or functional loss resulting from these stressors. A way to apply this
concept of frailty to older patients with cancer is beginning to emerge,
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Fig 1. Age distribution for patients enrolled onto National Cancer Institute (NCI)
adult cooperative group phase II and III treatment trials (all diseases) from 2001
to 2011. Percentage of patients enrolled in each age group is shown for each
year, as reported by cooperative groups to the NCI Clinical Data Update System
database (NCI Division of Cancer Treatment and Diagnosis) as of May 2012.
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Study End Points
Therapeutic phase III clinical trials focus primarily on efficacy as
measured by tumor response or overall and progression-free survival.
However, these standard trial end points do not capture a key concept
in geriatric medicine, which is maintenance of active life expectancy
(ie, number of years an individual lives independently without signif-
icant disability). The effects of cancer therapies on physical or cogni-
tive function could be just as important, if not more important, to
older patients than response or survival.36 The inclusion of functional
end points can aid in shared decision making by physicians and pa-
tients by identifying the most important areas for intervention.
Trial Designs: Opportunities, Strengths,
and Weaknesses
Several study designs were proposed to help fill the gaps in
knowledge regarding cancer therapy in older and/or frail adults. The
advantages and limitations of these trial designs are summarized in
Table 1.
Randomized controlled trial. The objective of this study design is
to determine the gold standard of treatment using a randomized
approach to ascertain the superiority (or lack of inferiority) of one
treatment over another. Randomized controlled trials (RCTs) for
older adults are particularly important if there are age-related changes
in cancer biology that may affect treatment efficacy. Furthermore, they
can include novel end points, such as composite measures of tolera-
bility and treatment efficacy. However, RCTs can be costly and lengthy
and require a large sample size.
Two approaches can be considered for the randomized design.
First, the study could specifically focus on older adults and address
questions that are most pertinent to the geriatric oncology population.
An example is CALGB (Cancer and Leukemia Group B) 49907 (Alli-
ance), which compared standard adjuvant polychemotherapy with
monochemotherapy in adjuvant treatment for adults age  65 years
with breast cancer. In this study, an adaptive Bayesian design was
used,37 which allows for interim analysis of the accumulated data at
specified time points. At these time points, if the treatment effect in
one of the treatment arms satisfies a predefined futility boundary,
accrual to that arm can be terminated while accrual to the other
treatment arm(s) can be continued until the planned total sample size
is reached. This study design is advantageous because of the potential
for a smaller sample size requirement if the underperforming study
arms are eliminated after interim data analysis.
The second approach is to accrue patients of all ages but
purposefully stratify enrollment into age groups representative of
the general population with the disease. An advantage of this
approach is that the study results are more generalizable to the
overall population with the disease. A disadvantage of this ap-
proach is that requiring enrollment of specific age strata may limit
accrual speed. Furthermore, the study objectives and end points
may not be tailored to the geriatric oncology population.
Prospective cohort study. In a prospective cohort study, the co-
hort can be defined by the host, tumor, or treatment characteristics,
depending on the research question. This design can be used to answer
commonly posed questions in geriatric oncology regarding the feasi-
bility, dosing, and toxicity of a selected regimen, particularly among
patients receiving treatment as standard of care. A significant limita-
tion is that this design does not identify the best treatment (ie, most
efficacious and least toxic), because there is no randomized compo-
nent. Furthermore, as with an RCT, significant data management
resources are required to accurately capture and enter the dosing and
toxicity data.
Another type of prospective cohort study is exemplified by
CALGB 369901, which prospectively observed older women with
nonmetastatic breast cancer receiving adjuvant treatment to under-
stand treatment decision-making, quality-of-life, and survivorship
issues.38 This study was open to accrual in parallel with CALGB
49907.37 Those patients who did not enroll onto 49907 were eligible
for this prospective cohort study.
Embedded study. An embedded study, also known as a correla-
tive or ancillary study, is placed within the infrastructure of a parent
study. An embedded study can be used to identify the characteristics of
those patients at high risk for toxicity and to evaluate the toxicity
profile of new drugs. An example is CALGB 361006, which embeds a
comprehensive GA within the schema of CALGB 11001,39 a trial
evaluating the efficacy of adding sorafenib tosylate to induction and
postremission chemotherapy in patients age  60 years with FLT3-
mutated acute myeloid leukemia. The goal of the companion sub-
study is to identify specific comprehensive GA measures that may
predict overall survival and treatment-related mortality for older
adults receiving this treatment. Several considerations in this study
design are important. First, if participation in the embedded study is
optional, a skewed sample may be accrued, limiting generalizability.
Furthermore, the sample size of the embedded study should be deter-
mined a priori to reach the target accrual necessary to identify a
vulnerable subgroup. A limitation of this design is that the parent
study may not be specifically targeted to older adults. In such a case,
there may be limited accrual of older adults to the embedded study.
Single-arm trial. Single-arm trials can be used to assess the
benefits and toxicities of specific drugs for which there are limited data
in older adults. Additional advantages of a one-arm trial design are
that novel end points such as the impact of therapy on function and
quality of life can be assessed, and age-related changes in the pharma-
cology of cancer treatment can be evaluated. The addition of a younger
cohort of patients can bolster the ability to identify age-related changes
in pharmacokinetics across the age spectrum. The disadvantage of a
single-arm trial is that it does not compare the study treatment with a
gold standard.
An example of a single-arm trial is CALGB 9762,40 a prospective
evaluation of the relationship between patient age and paclitaxel clin-
ical pharmacology. This study sought to prospectively evaluate the
association between patient age and the pharmacokinetics and toxicity
profile of paclitaxel, as well as to understand the relationship between
paclitaxel pharmacokinetics and toxicity.
Extended trial. The extended trial design is a novel concept
discussed at the conference, with no precedent to our knowledge. The
goal of the extended trial design is to obtain data regarding a new gold
standard within the older population. For example, once the results of
a phase III study have been reported, the age distribution of the
participants in the superior arm is examined. If the study failed to
accrue an age distribution similar to the population of individuals at
risk, the superior arm is reopened to accrue an adequate number of
older adults. This study design aims to fill the knowledge gap regarding
the tolerability of a new regimen in older cohorts. The limitation of
this (hypothetic) design is that there is no precedent for reopening a
study several years after the study has been closed. This would there-
fore require a shift in the present paradigm for the conduct of clinical
U13 Conference Report on Cancer and Aging Research
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trials. Furthermore, the extended trial design would not establish
age-related differences in treatment efficacy between study arms in-
cluded in the original randomized trial. Alternatively, if reopening a
phase III study is considered too large a barrier to overcome, phase IV
studies could potentially evaluate the tolerability of the new standard
in populations with the disease that were underrepresented in the
original study; however, there is no precedent for this approach either.
Considerations for Dosing Schema
The significant underrepresentation of older adults in US Food
and Drug Administration registration trials8,28 has led to a dearth of
information regarding the optimum dose and schedule of cancer
therapeutics for the geriatric population. Differences in treatment
patterns between older and younger adults have been noted.12-19 Con-
cerns about the risk of toxicity may influence a health care provider’s
willingness to deliver the full chemotherapy dose with the first cycle of
treatment, particularly if the treatment goal is palliation. In the geriat-
ric literature, the adage “start low and go slow” may increase both the
physician’s and older patient’s comfort with a new regimen, particu-
larly when there are concerns about heightened toxicity risks. A way of
applying this principle to geriatric oncology trials is to reduce the first
dose, then escalate to standard dosage if the patient tolerates the
treatment well. This approach was used in the FOCUS2 (Fluorouracil,
Oxaliplatin, and CPT-11 [irinotecan]: Use and Sequencing 2) trial41
for older and/or frail adults with metastatic colorectal cancer. A po-
tential downside of this approach is that patients would not receive a
standard dose upfront, which could compromise efficacy. However, if
dose escalation is performed rapidly, this is unlikely to have a major
impact. Furthermore, it is not clear that the dose-reduced approach is
associated with decreased toxicity. If this approach is used, it is favored
in patients who are receiving therapy for metastatic disease, not for
adjuvant treatment, where standard dosing should be used in those
undergoing treatment with curative intent.
Trial Designs to Predict Treatment Tolerability
The general goal of studies to predict treatment tolerability is to
develop risk-adapted strategies for treatment by identifying the profile
(by toxicity risk, life expectancy, and/or tumor biology) of individuals
who can or cannot tolerate a specific treatment. This optimizes the
benefit-to-risk ratio. The aging process is heterogeneous, making
chronologic age a relatively poor marker of overall physiologic and
health status. Inclusion of a GA can help to deconstruct this heteroge-
neity by providing information regarding independent predictors of
morbidity and mortality, such as functional status, comorbidities,
nutritional status, psychologic state, social support, and cognitive
function.42 These can be included as predictor and/or outcome vari-
ables. For example, the GA could be used at study entry as a predictor
of treatment tolerability. Furthermore, the GA could be collected in
longitudinal follow-up to understand the impact of treatment on GA
variables (eg, function or cognition). Three potential trial designs
were discussed.
All-comers design. A key question in geriatric oncology is
whether there is a subgroup of older patients who are at higher risk for
toxicity. This trial design enrolls all comers with the goal of identifying
the specific characteristics of patients who derive benefit from the
treatment without significant toxicity, typically defined as grade  3,
according to the NCI Common Terminology Criteria for Adverse
Events, or grade 2, determined a priori to be of relevance.
Enrichment design. If there is confidence that a specific group of
individuals is at high risk for toxicity, an enrichment design allows the
trial to accrue patients with those specific characteristics. To use an
enrichment design, there must be agreement about risk factors for
toxicity. However, a uniform definition of patients at high risk for
toxicity has not yet been formally established within the geriatric
oncology community. Recent research studies are starting to provide
an evidence-based definition.21,22
Marker-by-treatment interaction design. A marker-by-treatment
design compares the risks and benefits of two treatment strategies for
two groups of older patients: those predicted to be at low risk for
toxicity versus those predicted to be at high risk for toxicity, based on
a prespecified definition. At entry, eligible patients are stratified based
on this toxicity risk and are subsequently randomly assigned to the
treatment arms. In oncology clinical trials, a typical paradigm has been
to add treatments to the gold standard to see if the efficacy can be
improved. However, the cumulative addition of therapeutic agents
can increase the risk of toxicity. If the toxicity exceeds a threshold,
efficacy may be compromised because of the inability to deliver the
therapy. The marker-by-treatment design can help weigh the risks and
benefits of novel therapies (in comparison with the standard) between
patients with different predicted risks of toxicity. A disadvantage of
this approach is the requirement of a large sample to accomplish the
study objectives.
Facilitating Enrollment of Older Adults
Older age alone should not be a contraindication to clinical trial
enrollment; however, older adults are underrepresented in cancer
clinical trials.6,7,27,28,43 One study found that older age was the sole
reason why otherwise eligible patients were not offered clinical trial
enrollment.44 Often a combination of patient-, provider-, study-, and
system-related barriers may keep older patients with cancer from
participating in therapeutic clinical trials.45-51 For example, patient
nonparticipation has been attributed to wanting a different therapy,52
living too far from the cancer center,52,53 worrying about insurance
reimbursements,52,53 or being ruled ineligible because of poor perfor-
mance status, need for emergent therapy, or number of comorbid
conditions.53 A lack of social support or a reluctance to travel to
university centers where trials are most often conducted are additional
deterrents to trial enrollment among older patients.54-56
Nevertheless, attitudes of older patients with cancer have not
been shown to significantly result in lower enrollment. A majority of
older patients report a positive attitude toward cancer clinical trials,57
and a survey of patients age  70 years found that three quarters of
these patients are willing to participate in clinical trials.58 Physician
recommendations play an important role in patients’ decisions re-
garding trials,58 and physician bias can be one of the main barriers to
the enrollment of older patients.54
Overly restrictive eligibility criteria are also commonly cited as a
reason for accrual difficulties, particularly for older and/or frail pa-
tients. Criteria that are too stringent jeopardize the generalizability of a
study; however, criteria that are overly broad can jeopardize patient
safety and generate an overly heterogeneous study population, which
interferes with detecting a treatment effect. The reduction or elimina-
tion of irrelevant criteria that hinder enrollment and the better use of
instruments that assess prognosis and risks for toxicity can improve
inclusion criteria.
Hurria et al
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Difficulties in identifying appropriate clinical trials, as well as the
complexity of the trials themselves, can impede recruitment of older
adults. Reducing the complexity of study schemas as well as the num-
ber of correlative studies may increase study participation. The expe-
rience itself may also be enhanced by simply providing supportive
settings that include such things as soundproof curtains, bedside hear-
ing and visual assistance devices, nonskid floor surfaces that help
prevent falls, natural lighting conditions to counteract sensory losses,
safety measures geared for individuals with comorbidities, and re-
sources and support infrastructure for caregivers.59,60 Culturally ap-
propriate recruitment approaches and technology that allows remote
data collection could also improve recruitment by eliminating the
need for frequent travel to major medical centers. Collaboration be-
tween geriatricians and oncologists from the outset, as well as geriatric
training for support staff, would facilitate the design and implemen-
tation of clinical trials to make them more amenable to the participa-
tion of older and/or frail patients.
CANCER SURVIVORS: TOPIC FOR THE NEXT U13 CONFERENCE
The number of cancer survivors increased from almost 4 million in
1977 to 13.7 million in 2012, and this number is expected to reach 18
million in the next 10 years.61 Approximately 60% of today’s cancer
survivors are age  65 years,3 and this number will steadily increase
because of an overall rise in life expectancy and advances in early
detection and cancer treatment. Approximately 16% of new diagnoses
occur in individuals who already have a history of cancer, and this
proportion is expected to increase.62 There is much to learn about
caring for cancer survivors, accounting for both the risks of subse-
quent cancers as well as the immediate and longer-term effects
of treatment.
Therapeutic clinical trials can address these issues by gathering
pretreatment and follow-up data such as that captured in a geriatric
assessment, along with information on socioeconomic status and
access to health resources, social support (or more importantly,
among the aging population, social isolation), and modifiable factors
such as smoking history, nutrition status, signs of depression, and level
of physical activity. The next U13 conference (scheduled for May
2015) will address these questions.
DISCUSSION
Cancer is associated with aging, and although a majority of cancer
diagnoses occur in individuals age  65 years, these patients continue
to be underrepresented in cancer research and clinical trials. In addi-
tion, the standard clinical trial design rarely addresses end points of
particular interest to older adults (such as preservation of function).
To increase the enrollment of older adults onto clinical trials, clinical
trials must be developed specifically for those individuals who do not
meet the eligibility criteria or are not fit enough for enrollment onto
clinical trials focused on individuals of all ages.
We have presented the results of a recent U13 conference held by
CARG in collaboration with the NIA, the NCI, and the Alliance of
Clinical Trials in Oncology, including proposals for improved clinical
trial designs and their advantages and disadvantages for the geriatric
oncology population. These proposals can serve as a blueprint for
individuals who are entering or engaged in the field of geriatric oncol-
ogy research and help in the consideration of trial designs that are best
suited to answer the research questions they are posing. Ultimately,
there is hope that this ongoing conference series will contribute to
substantial enhancement of the evidence base so critical for the ade-
quate treatment of older and/or frail individuals with cancer.
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